LP-18: Challenges and Opportunities in Use of the Minipig for Nonclinical Pharmaceutical Development: Results of the Second IQ DruSafe Minipig Survey
Joanna Harding(AstraZeneca (United Kingdom)), Béatrice Gauthier(Sanofi (France)), David Clarke(University of Oxford), Kaushik Datta(Bristol-Myers Squibb (Germany)), Kevin J. French(GlaxoSmithKline (United States)), Drew Olaharski(Relay Therapeutics (United States)), Devon Strein(Boehringer Ingelheim (United States)), Michael W. Leach(Pfizer (United States)), Susanne Mohr(Roche (Switzerland)), Thierry D. Flandre(Novartis (Switzerland))
Cited by 0
Related Papers
Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2
|Journal of Pharmacology and Experimental Therapeutics|2010|313
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
|Regulatory Toxicology and Pharmacology|2022|32
Survey results on the use of the tissue cross-reactivity immunohistochemistry assay
|Regulatory Toxicology and Pharmacology|2010|24
Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors
|Journal of Medicinal Chemistry|2020|20
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
|Regulatory Toxicology and Pharmacology|2023|15